Dr. Roselle De Guzman is a medical oncologist and associate professor at the Manila Central University-FDTMF Hospital in Manila, Philippines. She is currently chair of the American Society of Clinical Oncology (ASCO) Asia Pacific Regional Council and member of the Annual Meeting Scientific Program Committee. She is an academic clinician with special interest in lung cancer and global oncology.

Dr. de Guzman has served on ASCO committees and working groups. She was chair of the Multidisciplinary Cancer Management Course, the International Development and Education Award (IDEA) Working Group, and was a member of the steering committee of ASCO International Affairs. She has participated in the ASCO Leadership Development Program and served on advisory panels including Resource Stratified Practice Guideline Advisory Group, COVID-19 Clinical Questions Advisory group, and Educational Book Expert Panel. She is an invited peer reviewer for international journals including BMJ, JAMA Oncology, JCO Global Oncology and The Lancet Regional Health.

Dr. Adnan A. Jabbar is a medical oncologist serving as the Section Head and Associate Professor in the Department of Oncology at the AKUH. He did his MBBS from Dow Medical College and PhD from RUSH University, Chicago, Illinois, following which he completed his residency in Internal Medicine from Nassau University Medical Center, New York. He received his Hematology and Medical Oncology fellowship training from Winship Cancer Institute Emory School of Medicine, Atlanta, Georgia. He is American Board certified in Internal Medicine and Medical Oncology. In addition to his clinical commitments Dr. Jabbar serves as Director of Oncology Research Committee (DRC) and represents the department on various other committees in AKU.

Dr. Thanyanan Reungwetwattana is a consultant at Division of Medical Oncology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Thailand. She received her medical degree, Thai Board of Internal Medicine, and Thai Subspecialty Board in Medical Oncology at Ramathibodi Hospital, Mahidol University, Thailand. After that, she spent 3 years from August 2009 to June 2012 as a clinical research fellow in thoracic malignancies and also obtained a Master’s Degree of Biomedical Science (Clinical Research Training Program) at the Mayo Clinic Cancer Center, Rochester, MN, USA. Subsequently, she extended her training as a Clinical Fellow in Advanced Medical Oncology focusing on Cancer Drug Development Program at Roswell Park Cancer Institute, NY, USA from July 2012 to July 2013.
Dr. Reungwetwattana’s research interests are in lung cancer and drug development which involve both in clinical and translational settings. Furthermore, Dr. Reungwetwattana has served as an editorial board member and committee of the Journal of Thoracic Oncology from June 2013 to present. She is also joining the Communication Committee of the International Association for the Study of Lung Cancer (IASLC) from 2015 to present and she has been the WCLC 2017, 2019, 2021 program committee. Currently she also serves as the regional organizing committee for WCLC 2020-2021. Furthermore, she is one of the steering committees of ATORG (Asian Thoracic Oncology Research Group). She recently received the Best Young Physician of the Year from The Royal College of Physicians of Thailand (RCPT) and she is also the National finalist of ASEAN-US Science Prize for Women 2020. Recently, she has joined the scientific committee of European Society for Medical Oncology (ESMO).

Dr. Navneet Singh MD DM is a pulmonologist and thoracic medical oncologist currently working as Additional Professor of Pulmonary Medicine at PGIMER, Chandigarh, India. Dr. Singh is the coordinator-cum-convener for PGIMER’s multidisciplinary thoracic oncology group that received the 2019 Lung Cancer Care Team Award (Overall Winner and Winner from Asia/Rest Of World) at the 20th World Conference on Lung Cancer in Barcelona, Spain. He is also a member of IASLC’s Staging & Prognostic Factors Committee. A past recipient of American Society of Clinical Oncology (ASCO)’s International Development & Education Award (IDEA), Dr. Singh served as Chair of ASCO's IDEA Steering group (2018-20) and is currently an invited member of ASCO's Special Awards Selection Committee. Currently, he is Co-Chair of ASCO’s Stage IV NSCLC Living Guidelines.

A/Prof Kate Sutherland is a Laboratory Head at The Walter and Eliza Hall Institute of Medical Research (WEHI), developing state-of-the-art preclinical models of lung cancer. Kate completed her PhD in 2005 before moving to The Netherlands Cancer Institute, where she undertook Postdoctoral studies in the laboratory of Prof Anton Berns. During this time Kate generated a series of adenoviral vectors that have the ability to target cancer-associated mutations to specific lung epithelial cell types. This innovative work advanced the field by identifying the cell-of-origin of the two main types of lung cancer. In 2013, Kate returned to WEHI to start her own laboratory dedicated to understanding tumour heterogeneity in lung cancer. In this time, she has developed new approaches and technologies to study lung cancer, leading to seminal findings on genetic drivers, the immune microenvironment and the role of the metabolome in these aggressive cancers. She has been the recipient of funding from Worldwide Cancer Research, NHMRC and the Victorian Cancer Agency to support her work in designing precision medicine approaches for lung cancer patients.

Prof. Rabab Gaafar is former Chair Medical Oncology Department , National Cancer Institute, Cairo (NCI), Cairo University in Egypt, former Board member of EORTC lung group, Board member of IMIG and ESMO regional representative for Egypt and North Africa since 2008 up till now and also ESMO Panel committee member,

Prof. Rabab Gaafar received her M.D. certification in Medical Oncology from the National Cancer Institute, Cairo University 1987. Prof. Rabab Gaafar is directing the Thoracic Oncology Program at NCI, Cairo and she was also heading the Early Detection Prevention Unit at the Institute from 2006-2010. She is past chairman of Quality Assurance in the Board of the European Organization for Research and Treatment of Cancer Lung Cancer Group (EORTC) that started 2006
till March 2015 .In the Board of IMIG since 2008 till now.

Prof. Rabab Gaafar has published more than 200 publications in National and International Journals and is in the Editorial Board for the journal Frontier in Thoracic Oncology and reviewer in many International journals such as Lung cancer, Eur Resp journal, Frontier in Thoracic oncology, journal Thoracic disease, journal of Clinical Practice , Journal of Advanced Research (JAR) , National Cancer Institute Journal Cairo , The BREAST. She is also reviewer for STDF projects in Egypt and board member of Reviewer Committee for Oncology publications as a prerequisite for the degree of professors and associate professors in Egypt. She had received the Medical Syndicate Award of Cairo in 2003 and that of Egypt in 2004. She received awards from Cairo University for distinguished publications in International peer-reviewed journals In 2007 , 2008, 2010 , 2011, 2012 and 2013 , 2014 and 2015, 2016, 2017, 2018, 2019, and 2020. She received award for best thesis supervision in Cairo University for the years 2007,2010,2013,2014. In the year 2009, she received The Cairo University Recognition Award in medical sciences , and in 2016, she received Cairo University Excellence Award in medical sciences. Included in Marquis Who”s Who in the world for the year (2011, 28th Edition) and year( 2013, 30th edition, year 2015. and 2020 . As of April 2013, she received award of Future Medical Authors (FMA) 2013 Advisor Award from Future Medical scholars for year 2012 and 2013. Recently she is now is president of the Egyptian Society of Respiratory Neoplasm (ESRN) in Egypt. She is also heading the committee of promotion of staff in oncology as a prerequisite for the degree of professors and associate professors in Egypt.

Prof. Rabab Gaafar is interested in solid tumors in general mainly Lung Cancer, Mesothelioma, and Breast Cancer, targeted therapy and new drugs, translational research, prevention and early detection of cancer and is Principal Investigator in many International clinical studies. She is having more than 200 National, International publications (Total cytationd 2424 and H- index 22) in Scopus

Dr. Lori Pierce attended Duke University School of Medicine and completed a Radiation Oncology residency and chief residency at the Hospital of the University of Pennsylvania. She then was appointed as a Senior Investigator at the National Cancer Institute, National Institutes of Health in Bethesda, MD from 1990-1992. In 1992, Dr. Pierce joined the faculty of the University of Michigan where she is currently Professor with tenure in Radiation Oncology. Since coming to Michigan, she has served as residency director and clinical director in the Department of Radiation Oncology. In August 2005, Dr. Pierce was appointed by the University of Michigan Board of Regents to be Vice Provost for Academic and Faculty Affairs, a position she still holds.

Dr. Pierce has dedicated her career to the treatment of breast cancer patients. Her research focuses on the use of radiotherapy in the multi-modality treatment of breast cancer, with emphasis on intensity modulated radiotherapy in node positive breast cancer, the use of radiosensitizing agents, and the outcomes of women treated with radiation for breast cancer who are carriers of a BRCA1/2 breast cancer susceptibility gene. She serves as Director of the Michigan Radiation Oncology Quality Consortium (MROQC), a quality consortium of radiation oncology practices across the state of Michigan that seeks to establish best practices in the treatment of breast and lung cancers. This initiative is funded by Blue Cross Blue Shield of Michigan and Blue Care Network. She is a previous member of the NCI Breast Cancer Steering Committee and previously served on the Steering Committee for the Early Breast Cancer Trialists’ Collaborative Group at the University of Oxford. She continues to serve on many U.S. breast cancer boards and committees and was recently selected to be a member of the Breast Cancer Research Foundation Scientific Advisory Board.

Dr. Pierce has published over 200 manuscripts and book chapters and has received numerous teaching awards from the University of Michigan and multiple national organizations. Honors include receipt of the European Society of Therapeutic Radiology and Oncology travel award, the American Medical Association Women Physician Mentor Award, the American Association for Women Radiologists’ Marie Curie Award, the Conquer Cancer Foundation Endowed Women Who Conquer Cancer Mentorship Award, and selection as a Susan G. Komen for the Cure Scholar. Most recently, Dr. Pierce was elected to the National Academy of Medicine, Class of 2018. She was also selected as the 2019 Woman of the Year by the United Way of Washtenaw County in Michigan. In 2018, she was elected president-elect of the American Society of Clinical Oncology, the largest organization of oncology professionals in the world, and served as president in 2020-2021. She is currently Chair of the Board.

Deborah Doroshow, MD, PhD is Assistant Professor of Medicine at the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai. She divides her clinical practice and research between the Center for Thoracic Oncology, where she sees patients with lung cancer, and the Early Phase Trials Unit, where she sees patients with a variety of solid tumors on phase 1 and 2 trials of novel agents. Her research, for which she was awarded a 2021 ASCO Career Development Award, focuses on the use of targeted therapies to treat cancer and examines the use of novel agents to target DNA damage and repair processes.